Member Directory


601 Walnut St
Suite 440 W
Philadelphia, PA 19106

Main Contact: Mr. John Furey

Business Description:

The approach is an autologous, cell-based treatment that activates the full array of patient-specific antigens, resulting in both an innate and adaptive immune response. The company’s lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer with a significant unmet need. In parallel, the company is also progressing the platform in a select number of additional solid tumors where the unmet need remains great and where initial immunotherapy approaches have often failed to provide a significant benefit.

Business Type:

Business Information:

  • Established in 2015
  • Privately Owned
  • Member Since 2020

My Benefit Advisor
PA Drug Card
Go to Top